Highest-materiality recent filing
Approved reverse stock split at ratio 1:1.1 to 1:100; 5,067,304 for, 2,280,497 against.
PharmaCyte Biotech receives Nasdaq notice of non-compliance with $1.00 minimum bid price
Notice received Dec 1, 2025; stock closed below $1.00 for 30 consecutive business days.
PharmaCyte acquires $3M convertible stake in Q/C Technologies; Q/C has going concern
PharmaCyte bought Q/C Series H convertible preferred shares and warrants for $3M, convertible into 600,000 common shares each.
PharmaCyte stockholders authorize share issuance and approve 2.25M share increase to equity plan
Stockholders authorized issuance of shares underlying convertible preferred stock and warrants per August 2025 SPA (1,649,395 for, 249,100 against).
PharmaCyte purchased $3M of TNF Series H convertible preferred shares (convertible at $5) and warrants for 600,000 common shares at $5 exercise price.
PharmaCyte raises $7M in private placement of Series C convertible preferred and warrants
Sale of 7,000 shares of Series C preferred (stated value $1,000) convertible into 7M common at $1.00 per share.
PharmaCyte Biotech annual meeting elects directors, ratifies auditor, approves exec compensation
Annual meeting held Apr 24, 2025; quorum of 3,222,988 shares (~46.92%) present.
Marcum LLP resigned as independent auditor on Feb 21, 2025, effective upon CBIZ CPAs P.C. acquiring Marcum's attest business.
PharmaCyte invests $7M in MyMD for convertible preferred stock and warrants
Invests $7M for Series G Convertible Preferred Stock convertible into 3,854,626 MyMD common shares at $1.816 per share.
Quorum of 53.41% of outstanding shares represented at the April 29, 2024 annual meeting.
PharmaCyte grants $100K cash and 170K options to CEO, $50K cash and 85K options to CFO
One-time grant to Joshua Silverman (Interim CEO): $100,000 cash and options to purchase 170,000 shares at $2.18/share.
PharmaCyte Biotech invests $5M in Femasys, expanding strategy to utilize $74.6M cash
PharmaCyte (PMCB) purchases $5M senior unsecured convertible notes from Femasys (FEMY) at 6% interest, maturing in 2 years.
PharmaCyte Biotech engages Marcum LLP as new independent auditor after Armanino resignation
Armanino resigned as independent auditor on August 1, 2023, citing exit from public company audit practice.
PharmaCyte shareholders approve authorized share increase to 200M and financing-related issuance
Shareholders approved issuance of shares ≥20% of outstanding related to May 2023 Securities Purchase Agreement (convertible preferred & warrants).
Auditor Armanino LLP resigns due to exit from public audits; no disagreements
Armanino resigned effective upon new auditor appointment or filing of Q for Jan 31, 2024.
PharmaCyte Biotech postpones special meeting to Aug 31; adopts bylaw amendment
Bylaw amendment allows board to fix record date for adjourned meetings under Nevada law.
Raises ~$35M via sale of 35,000 Series B convertible preferred shares and warrants to existing investors.
PharmaCyte Biotech authorizes new $10M share repurchase program
Board authorized repurchase of up to $10M of common stock, effective immediately for two years.
PharmaCyte Biotech shareholders approve reverse stock split, increase authorized shares to 133M
Reverse stock split at ratio of 1:5 to 1:20 approved with 11,385,563 votes for, 2,067,045 against.
PharmaCyte appoints Robert Weinstein to Board, removes cumulative voting
Robert Weinstein appointed to Board on Nov 14, 2022; chairs Audit Committee and will join Nominating Committee if elected at Dec 28, 2022 annual meeting.
Director Jack E. Stover resigns from PharmaCyte Biotech board effective Nov 1, 2022
Jack E. Stover resigned from the board of directors effective November 1, 2022.
PharmaCyte CSO resigns; board sets annual meeting Dec 28, continues $10M buyback
CSO Gerald W. Crabtree resigned effective Oct 12, 2022; receives $29,694.88 in accrued wages, PTO, and 3 months base salary.
CEO Kenneth Waggoner resigned effective Oct 6; separation agreement provides $216,667 lump sum and $433,333 consulting payments over 12 months.
PharmaCyte (PMCB) reaches cooperation deal with Iroquois; appoints five new independent directors
Five prior directors resigned; five new directors appointed to reconstituted 7-member board effective Aug 15, 2022.
Iroquois Capital, a 7% holder, seeks to expand board from 7 to 15 and elect 8 nominees to gain control of $80M+ cash.
Pilot study in two Yorkshire pigs evaluates microcatheter delivery of CypCaps into pancreatic arterial system.
PharmaCyte reports positive interim results in malignant ascites mouse model study
Study conducted by Heidelberg Pharma using colon carcinoma cells from Austrianova Master Cell Bank in mice.
PharmaCyte Biotech reports FY2022 net loss of $4.2M; cash at $85.4M; authorizes $10M buyback
Cash and cash equivalents of $85.4M as of April 30, 2022; no debt mentioned.
PharmaCyte defends board and strategy against Iroquois Capital; accelerates pancreatic cancer trial
Company expects to begin Phase 2b pancreatic cancer trial immediately upon FDA lifting clinical hold, saving ~6 months.
PharmaCyte Biotech sets 2022 Annual Meeting for Aug 25; proposals due June 24
2022 Annual Meeting of Stockholders scheduled for August 25, 2022.
PharmaCyte raises CEO and CFO salaries; Nasdaq confirms listing compliance
CEO Kenneth Waggoner salary increased from $375K to $520K, retroactive to Jan 1, 2022.
PharmaCyte Biotech appoints Dr. Matthias Löhr to Board to fill vacancy from Yuen's death
Dr. Löhr appointed to Board on March 31, 2022; vacancy created by death of Thomas C.K. Yuen.
Company made a corporate presentation available on its website for investor and analyst use.
PharmaCyte Biotech receives Nasdaq board independence deficiency notice after director death
Independent director Thomas C.K. Yuen passed away Feb 13, 2022, triggering noncompliance with Nasdaq Listing Rule 5605(b)(1).
Pharmacyte Biotech notifies Nasdaq of board independence non-compliance after director death
Board member Thomas C.K. Yuen died Feb 13, 2022; company notified Nasdaq Feb 15, 2022.
PharmaCyte posts corporate presentation on website; no material updates disclosed
Filed under Item 7.01; presentation available on company website.
PharmaCyte Biotech raises $70M in registered direct offering and private placement
Gross proceeds ~$70M from sale of 8.43M shares and 5.57M pre-funded warrants at $5.00 per share.
PharmaCyte Biotech announces Nasdaq uplisting and pricing of $15M public offering at $4.25/unit
Common stock begins trading on Nasdaq Capital Market under PMCB on August 10, 2021.
PharmaCyte Biotech reports preliminary FY2021 net loss of $3.6M, cash $2.2M
Net loss for FY2021 was approx. $3.6M ($2.45 loss per share) vs. $3.8M ($4.23 loss per share) in FY2020.
PharmaCyte Biotech effects 1-for-1,500 reverse stock split, reduces outstanding shares to ~1.6M
Reverse stock split ratio 1:1,500; outstanding shares reduced from ~2.4B to ~1.6M.
PharmaCyte shareholders approve 50B common share authorization increase and bylaw amendment
Authorized common stock increased to 50 billion shares ($0.0001 par); preferred stock to 10 million shares.
On November 14, 2022, the board of directors (the “Board”) of PharmaCyte Biotech, Inc. (the “Company”) increased the size of the Board to six members and appointed Robert Weinstein to serve as a member of the Board, effective immediately.
On November 1, 2022, Jack E. Stover notified PharmaCyte Biotech, Inc. (the “Company”) of his decision to resign from the board of directors of the Company, effective immediately.
On October 12, 2022 (the “Separation Date”), Gerald W. Crabtree, the Chief Scientific Officer of PharmaCyte Biotech , Inc. ( the “Company”), resigned from his position as an employee of the Company.
Effective October 6, 2022, the Board appointed Joshua N. Silverman, a director on the Board since August 2022, as interim Chairman of the Board, interim Chief Executive Officer and interim President of the Company.
Kenneth L. Waggoner, the Chief Executive Officer, President and General Counsel of PharmaCyte Biotech , Inc. ( the “Company”) resigned from his position as an employee of the Company and its direct and indirect subsidiaries and affiliates (collectively, the “Company Group”) and as a director on the Board of Directors of the Company (the “Board”).
effective August 15, 2022, the Board appointed each of Messrs. Schechter, Silverman, Allen, Farb and Stover as independent members of the Board.
effective August 15, 2022, each of Dr. Matthias Löhr, Dr. Tong, Mr. Liquard, Dr. Crabtree, and Mr. Trujillo resigned as members of the Board.
effective August 15, 2022, the Board appointed each of Messrs. Schechter, Silverman, Allen, Farb and Stover as independent members of the Board.
effective August 15, 2022, the Board appointed each of Messrs. Schechter, Silverman, Allen, Farb and Stover as independent members of the Board.
effective August 15, 2022, each of Dr. Matthias Löhr, Dr. Tong, Mr. Liquard, Dr. Crabtree, and Mr. Trujillo resigned as members of the Board.
effective August 15, 2022, each of Dr. Matthias Löhr, Dr. Tong, Mr. Liquard, Dr. Crabtree, and Mr. Trujillo resigned as members of the Board.
effective August 15, 2022, the Board appointed each of Messrs. Schechter, Silverman, Allen, Farb and Stover as independent members of the Board.
Max materiality 0.85 · Median 0.50 · Most common event other_material